uniQure (NASDAQ:QURE) Earns “Outperform” Rating from Royal Bank of Canada

uniQure (NASDAQ:QURE)‘s stock had its “outperform” rating reissued by Royal Bank of Canada in a report issued on Tuesday,Benzinga reports. They currently have a $24.00 price target on the biotechnology company’s stock. Royal Bank of Canada’s price target points to a potential upside of 65.47% from the company’s previous close.

Several other equities analysts also recently weighed in on the company. Leerink Partners raised their price objective on uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th. Stifel Nicolaus raised their price target on uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, December 16th. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research report on Tuesday, December 10th. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and raised their target price for the company from $20.00 to $52.00 in a report on Tuesday, December 10th. Finally, Mizuho upped their price target on shares of uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a report on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, uniQure presently has a consensus rating of “Moderate Buy” and an average price target of $34.38.

uniQure Price Performance

Shares of NASDAQ QURE traded up $0.45 during trading on Tuesday, hitting $14.50. 298,005 shares of the company were exchanged, compared to its average volume of 1,274,328. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. uniQure has a 1 year low of $3.73 and a 1 year high of $19.18. The company has a market cap of $706.92 million, a price-to-earnings ratio of -2.92 and a beta of 0.41. The firm’s fifty day moving average price is $12.22 and its 200 day moving average price is $8.48.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The firm had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. On average, sell-side analysts expect that uniQure will post -3.74 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the sale, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.74% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of QURE. FNY Investment Advisers LLC acquired a new stake in uniQure during the fourth quarter worth about $88,000. RTW Investments LP acquired a new stake in uniQure during the 3rd quarter worth approximately $49,000. China Universal Asset Management Co. Ltd. raised its holdings in uniQure by 57.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 3,663 shares during the period. Atria Investments Inc acquired a new position in uniQure during the third quarter valued at approximately $53,000. Finally, Quarry LP purchased a new stake in uniQure during the third quarter worth approximately $58,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.